Bahadır TURAN, Onur Burak DURSUN, İbrahim Selçuk ESİN, Şaban Oğuz DEMİRDÖĞEN

Atomoksetine bağlı üriner retansiyon: Bir olgu sunumu

Dikkat eksikliği ve hiperaktivite bozukluğunun (DEHB) ilk basamak tedavilerinden biri olan atomoksetin, presinaptik nöradrenalin taşıyıcısını inhibe ederek noradrenalin geri alımını engelleyen bir non-psikotik ilaçtır. Yan etki profili genel olarak düşük olan bu ilacın üriner sistem üzerine olan etkileri oldukça nadir olup literatürde bugüne kadar yalnız dört olgu bildirilmiştir. Bu olgu sunumunda, DEHB nedeniyle atomoksetin kullanan yedi yaşındaki bir hastada ilacın neden olduğu akut üriner retansiyondan söz edilmiştir. (Anadolu Psikiyatri Derg 2020; 21(2):222-224)

Atomoxetine-induced urinary retention: a case report

Atomoxetine is one of the first-line treatments for attention deficit and hyperactivity disorder (ADHD) and is a nonpsychotic drug that reduces noradrenalin reuptake by selectively inhibiting presynaptic noradrenaline transporter.This agent, which has a good history of security, rarely produces side effects related to the urinary system. Although this rare side effect has been mentioned previously in the adults using atomoxetine, this effect is not fully known in children and adolescents. Until today, there are only four cases in the literature related to this subject. This case report will mention about the acute urinary retention, which is thought to be induced by the drug used, in a 7-yearold patient receiving atomoxetine treatment due to ADHD. (Anatolian Journal of Psychiatry 2020; 21(2):222-224)

PDF

___

1. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108(5):e83-e.
2. Çivilibal M, Aksu BY. Güncel Kılavuzlar Eşliğinde Akut Böbrek Hasarı. Med Bull Haseki 2015; 53(2):116-119.
3. Nevo A, Mano R, Livne PM, Sivan B, Ben-Meir D. Urinary retention in children. Urology 2014; 84(6):1475-1479.
4. Drake MJ, Nixon PM, Crew JP. Drug-induced bladder and urinary disorders. Drug Saf 1998; 19(1):45-55.
5. Verhamme KM, Sturkenboom MC, Stricker BHC, Bosch R. Drug-induced urinary retention. Drug Saf 2008; 31(5):373-88.
6. Desarkar P, Sinha VK. Acute urinary retention associated with atomoxetine use. Aust N Z J Psychiatry 2006; 40(10):936.
7. Şahin N, Altun H. Urinary retention associated with atomoxetine use: a case report. J Clin Anal Med 2015; 6(Suppl.5):659-661.
8. Mutlu C, Yorbik O, Ipek H, Tanju IA. Acute urinary retention associated with increased dose of atomoxetine in a child: a case report. Klin Psikofarmakol Bull 2015; 25(3):299-301.
9. Gandhi R, Narang P, Lippmann S. Urinary hesitancy associated with atomoxetine. Prim Care Companion CNS Disord 2017; 19(5).